The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer

Gleason score (GS), as well as other prognostic and diagnostic modalities, can predict the possibility of tumor growth and metastasis during the life of patients with prostate cancer. Based on the prostate biopsy GS, clinicians choose the most appropriate therapy for managing patients. The objective...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urology journal 2021-07, Vol.18 (4), p.395-399
Hauptverfasser: Abedi, Amir Reza, Basiri, Abbas, Shakhssalim, Nasser, Sadri, Ghazal, Ahadi, Mahsa, Hojjati, Seyyed Ali, Sheykhzadeh, Samad, Askarpour, Sajjad, Ghiasy, Saleh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 399
container_issue 4
container_start_page 395
container_title Urology journal
container_volume 18
creator Abedi, Amir Reza
Basiri, Abbas
Shakhssalim, Nasser
Sadri, Ghazal
Ahadi, Mahsa
Hojjati, Seyyed Ali
Sheykhzadeh, Samad
Askarpour, Sajjad
Ghiasy, Saleh
description Gleason score (GS), as well as other prognostic and diagnostic modalities, can predict the possibility of tumor growth and metastasis during the life of patients with prostate cancer. Based on the prostate biopsy GS, clinicians choose the most appropriate therapy for managing patients. The objective of this cross-sectional study was to determine the discrepancy between needle biopsy and radical prostatectomy GS and to identify its predictive factors among the Iranian population. A total of 1147 patients who underwent radical prostatectomy from 2009 to 2019 were initially enrolled in this study. After consideration of the inclusion and exclusion criteria, 439 patients were finally included. The demographic variables and clinical data including age, PSA level, prostate volume, PSA density, GS derived from ultrasonography-guided core needle biopsy specimen, and GS derived from radical prostatectomy specimen were collected from the medical records of patients with prostate adenocarcinoma and were reviewed by a urology resident. Statistical analysis was done by using the Social Sciences Software version 21. The average age of patients was 64.5 years (range 48-84 years), and the average preoperative PSA level was 14.8 ng/mL. On histopathological examination, no changes in GS were observed in 237 (53.9%) patients, whereas GS was upgraded in 144 (32.8%) patients and downgraded in 58 (13.2%) patients at radical prostatectomy. The number of patients who had extracapsular extension, seminal vesicle invasion and positive lymph nodes was significantly higher in the upgraded group compared with the non-upgraded group.  Conclusion: In this study, there was a steady decrease in GS upgrading with the prostate size extending up to 49.7 g. There was also an association between downgrading and extending prostate size. Due to the greater risk of high-grade disease in men with small prostates, smaller prostate bulks are most probably upgraded after radical prostatectomy. A higher maximum percentage of involvement per core was an independent predictive factor of upgrading from biopsy grade 1 to grade ≥ 2. Our study showed that patients' age was not predictive of upgrading, which is consistent with other studies. Also, we demonstrated a non-significant relationship between PSA level and upgraded GS. Findings in this study did not demonstrate a significant relationship between PSA level and upgrading.
doi_str_mv 10.22037/uj.v16i7.5985
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2434479358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2819508523</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-bb7c2d14d3f1878138fc0bd315d15344d5444f2fe9c4471819b2f684f24dbcb93</originalsourceid><addsrcrecordid>eNpdkE1Lw0AQhhdRbK1ePcqCFy-p2a9kc9SqVShatIK3sNmd0JR0E7MbS_69C1YPnmbm5eFhZhA6J_GU0pil1_1m-kWSKp2KTIoDNCYpE5HgycfhvicsliN04twmjkUYkmM0YjTNJGVkjOxqDfiucrqDVlk94AL8DsDiZwBTA76tmtYNWFmDX5WptKrxsmucVx60b7YDntegXGPxm246wJXFS-UrsN7hXeXXfzCeBTt0p-ioVLWDs32doPeH-9XsMVq8zJ9mN4uopSzzUVGkmhrCDSuJTCVhstRxYRgRhgjGuRGc85KWkGnOUyJJVtAykSHiptBFxibo6sfbds1nD87n23Aj1LWy0PQupzxY0owJGdDLf-im6TsbtstpEItYCsoCdbGn-mILJm-7aqu6If_9JPsGlUZ1pA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2819508523</pqid></control><display><type>article</type><title>The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Abedi, Amir Reza ; Basiri, Abbas ; Shakhssalim, Nasser ; Sadri, Ghazal ; Ahadi, Mahsa ; Hojjati, Seyyed Ali ; Sheykhzadeh, Samad ; Askarpour, Sajjad ; Ghiasy, Saleh</creator><creatorcontrib>Abedi, Amir Reza ; Basiri, Abbas ; Shakhssalim, Nasser ; Sadri, Ghazal ; Ahadi, Mahsa ; Hojjati, Seyyed Ali ; Sheykhzadeh, Samad ; Askarpour, Sajjad ; Ghiasy, Saleh</creatorcontrib><description>Gleason score (GS), as well as other prognostic and diagnostic modalities, can predict the possibility of tumor growth and metastasis during the life of patients with prostate cancer. Based on the prostate biopsy GS, clinicians choose the most appropriate therapy for managing patients. The objective of this cross-sectional study was to determine the discrepancy between needle biopsy and radical prostatectomy GS and to identify its predictive factors among the Iranian population. A total of 1147 patients who underwent radical prostatectomy from 2009 to 2019 were initially enrolled in this study. After consideration of the inclusion and exclusion criteria, 439 patients were finally included. The demographic variables and clinical data including age, PSA level, prostate volume, PSA density, GS derived from ultrasonography-guided core needle biopsy specimen, and GS derived from radical prostatectomy specimen were collected from the medical records of patients with prostate adenocarcinoma and were reviewed by a urology resident. Statistical analysis was done by using the Social Sciences Software version 21. The average age of patients was 64.5 years (range 48-84 years), and the average preoperative PSA level was 14.8 ng/mL. On histopathological examination, no changes in GS were observed in 237 (53.9%) patients, whereas GS was upgraded in 144 (32.8%) patients and downgraded in 58 (13.2%) patients at radical prostatectomy. The number of patients who had extracapsular extension, seminal vesicle invasion and positive lymph nodes was significantly higher in the upgraded group compared with the non-upgraded group.  Conclusion: In this study, there was a steady decrease in GS upgrading with the prostate size extending up to 49.7 g. There was also an association between downgrading and extending prostate size. Due to the greater risk of high-grade disease in men with small prostates, smaller prostate bulks are most probably upgraded after radical prostatectomy. A higher maximum percentage of involvement per core was an independent predictive factor of upgrading from biopsy grade 1 to grade ≥ 2. Our study showed that patients' age was not predictive of upgrading, which is consistent with other studies. Also, we demonstrated a non-significant relationship between PSA level and upgraded GS. Findings in this study did not demonstrate a significant relationship between PSA level and upgrading.</description><identifier>ISSN: 1735-1308</identifier><identifier>EISSN: 1735-546X</identifier><identifier>DOI: 10.22037/uj.v16i7.5985</identifier><identifier>PMID: 32798231</identifier><language>eng</language><publisher>Iran: Urology and Nephrology Research Center</publisher><subject>Aged ; Aged, 80 and over ; Biopsy ; Biopsy, Needle ; Cancer surgery ; Cross-Sectional Studies ; Humans ; Iran ; Male ; Middle Aged ; Neoplasm Grading ; Prostate ; Prostate cancer ; Prostate-Specific Antigen ; Prostatectomy ; Prostatic Neoplasms - surgery ; Retrospective Studies ; Seminal Vesicles ; Urological surgery</subject><ispartof>Urology journal, 2021-07, Vol.18 (4), p.395-399</ispartof><rights>Copyright Urology and Nephrology Research Center Jul-Aug 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32798231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abedi, Amir Reza</creatorcontrib><creatorcontrib>Basiri, Abbas</creatorcontrib><creatorcontrib>Shakhssalim, Nasser</creatorcontrib><creatorcontrib>Sadri, Ghazal</creatorcontrib><creatorcontrib>Ahadi, Mahsa</creatorcontrib><creatorcontrib>Hojjati, Seyyed Ali</creatorcontrib><creatorcontrib>Sheykhzadeh, Samad</creatorcontrib><creatorcontrib>Askarpour, Sajjad</creatorcontrib><creatorcontrib>Ghiasy, Saleh</creatorcontrib><title>The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer</title><title>Urology journal</title><addtitle>Urol J</addtitle><description>Gleason score (GS), as well as other prognostic and diagnostic modalities, can predict the possibility of tumor growth and metastasis during the life of patients with prostate cancer. Based on the prostate biopsy GS, clinicians choose the most appropriate therapy for managing patients. The objective of this cross-sectional study was to determine the discrepancy between needle biopsy and radical prostatectomy GS and to identify its predictive factors among the Iranian population. A total of 1147 patients who underwent radical prostatectomy from 2009 to 2019 were initially enrolled in this study. After consideration of the inclusion and exclusion criteria, 439 patients were finally included. The demographic variables and clinical data including age, PSA level, prostate volume, PSA density, GS derived from ultrasonography-guided core needle biopsy specimen, and GS derived from radical prostatectomy specimen were collected from the medical records of patients with prostate adenocarcinoma and were reviewed by a urology resident. Statistical analysis was done by using the Social Sciences Software version 21. The average age of patients was 64.5 years (range 48-84 years), and the average preoperative PSA level was 14.8 ng/mL. On histopathological examination, no changes in GS were observed in 237 (53.9%) patients, whereas GS was upgraded in 144 (32.8%) patients and downgraded in 58 (13.2%) patients at radical prostatectomy. The number of patients who had extracapsular extension, seminal vesicle invasion and positive lymph nodes was significantly higher in the upgraded group compared with the non-upgraded group.  Conclusion: In this study, there was a steady decrease in GS upgrading with the prostate size extending up to 49.7 g. There was also an association between downgrading and extending prostate size. Due to the greater risk of high-grade disease in men with small prostates, smaller prostate bulks are most probably upgraded after radical prostatectomy. A higher maximum percentage of involvement per core was an independent predictive factor of upgrading from biopsy grade 1 to grade ≥ 2. Our study showed that patients' age was not predictive of upgrading, which is consistent with other studies. Also, we demonstrated a non-significant relationship between PSA level and upgraded GS. Findings in this study did not demonstrate a significant relationship between PSA level and upgrading.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biopsy</subject><subject>Biopsy, Needle</subject><subject>Cancer surgery</subject><subject>Cross-Sectional Studies</subject><subject>Humans</subject><subject>Iran</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Prostate</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Retrospective Studies</subject><subject>Seminal Vesicles</subject><subject>Urological surgery</subject><issn>1735-1308</issn><issn>1735-546X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkE1Lw0AQhhdRbK1ePcqCFy-p2a9kc9SqVShatIK3sNmd0JR0E7MbS_69C1YPnmbm5eFhZhA6J_GU0pil1_1m-kWSKp2KTIoDNCYpE5HgycfhvicsliN04twmjkUYkmM0YjTNJGVkjOxqDfiucrqDVlk94AL8DsDiZwBTA76tmtYNWFmDX5WptKrxsmucVx60b7YDntegXGPxm246wJXFS-UrsN7hXeXXfzCeBTt0p-ioVLWDs32doPeH-9XsMVq8zJ9mN4uopSzzUVGkmhrCDSuJTCVhstRxYRgRhgjGuRGc85KWkGnOUyJJVtAykSHiptBFxibo6sfbds1nD87n23Aj1LWy0PQupzxY0owJGdDLf-im6TsbtstpEItYCsoCdbGn-mILJm-7aqu6If_9JPsGlUZ1pA</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Abedi, Amir Reza</creator><creator>Basiri, Abbas</creator><creator>Shakhssalim, Nasser</creator><creator>Sadri, Ghazal</creator><creator>Ahadi, Mahsa</creator><creator>Hojjati, Seyyed Ali</creator><creator>Sheykhzadeh, Samad</creator><creator>Askarpour, Sajjad</creator><creator>Ghiasy, Saleh</creator><general>Urology and Nephrology Research Center</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20210701</creationdate><title>The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer</title><author>Abedi, Amir Reza ; Basiri, Abbas ; Shakhssalim, Nasser ; Sadri, Ghazal ; Ahadi, Mahsa ; Hojjati, Seyyed Ali ; Sheykhzadeh, Samad ; Askarpour, Sajjad ; Ghiasy, Saleh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-bb7c2d14d3f1878138fc0bd315d15344d5444f2fe9c4471819b2f684f24dbcb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biopsy</topic><topic>Biopsy, Needle</topic><topic>Cancer surgery</topic><topic>Cross-Sectional Studies</topic><topic>Humans</topic><topic>Iran</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Prostate</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Retrospective Studies</topic><topic>Seminal Vesicles</topic><topic>Urological surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abedi, Amir Reza</creatorcontrib><creatorcontrib>Basiri, Abbas</creatorcontrib><creatorcontrib>Shakhssalim, Nasser</creatorcontrib><creatorcontrib>Sadri, Ghazal</creatorcontrib><creatorcontrib>Ahadi, Mahsa</creatorcontrib><creatorcontrib>Hojjati, Seyyed Ali</creatorcontrib><creatorcontrib>Sheykhzadeh, Samad</creatorcontrib><creatorcontrib>Askarpour, Sajjad</creatorcontrib><creatorcontrib>Ghiasy, Saleh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Urology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abedi, Amir Reza</au><au>Basiri, Abbas</au><au>Shakhssalim, Nasser</au><au>Sadri, Ghazal</au><au>Ahadi, Mahsa</au><au>Hojjati, Seyyed Ali</au><au>Sheykhzadeh, Samad</au><au>Askarpour, Sajjad</au><au>Ghiasy, Saleh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer</atitle><jtitle>Urology journal</jtitle><addtitle>Urol J</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>18</volume><issue>4</issue><spage>395</spage><epage>399</epage><pages>395-399</pages><issn>1735-1308</issn><eissn>1735-546X</eissn><abstract>Gleason score (GS), as well as other prognostic and diagnostic modalities, can predict the possibility of tumor growth and metastasis during the life of patients with prostate cancer. Based on the prostate biopsy GS, clinicians choose the most appropriate therapy for managing patients. The objective of this cross-sectional study was to determine the discrepancy between needle biopsy and radical prostatectomy GS and to identify its predictive factors among the Iranian population. A total of 1147 patients who underwent radical prostatectomy from 2009 to 2019 were initially enrolled in this study. After consideration of the inclusion and exclusion criteria, 439 patients were finally included. The demographic variables and clinical data including age, PSA level, prostate volume, PSA density, GS derived from ultrasonography-guided core needle biopsy specimen, and GS derived from radical prostatectomy specimen were collected from the medical records of patients with prostate adenocarcinoma and were reviewed by a urology resident. Statistical analysis was done by using the Social Sciences Software version 21. The average age of patients was 64.5 years (range 48-84 years), and the average preoperative PSA level was 14.8 ng/mL. On histopathological examination, no changes in GS were observed in 237 (53.9%) patients, whereas GS was upgraded in 144 (32.8%) patients and downgraded in 58 (13.2%) patients at radical prostatectomy. The number of patients who had extracapsular extension, seminal vesicle invasion and positive lymph nodes was significantly higher in the upgraded group compared with the non-upgraded group.  Conclusion: In this study, there was a steady decrease in GS upgrading with the prostate size extending up to 49.7 g. There was also an association between downgrading and extending prostate size. Due to the greater risk of high-grade disease in men with small prostates, smaller prostate bulks are most probably upgraded after radical prostatectomy. A higher maximum percentage of involvement per core was an independent predictive factor of upgrading from biopsy grade 1 to grade ≥ 2. Our study showed that patients' age was not predictive of upgrading, which is consistent with other studies. Also, we demonstrated a non-significant relationship between PSA level and upgraded GS. Findings in this study did not demonstrate a significant relationship between PSA level and upgrading.</abstract><cop>Iran</cop><pub>Urology and Nephrology Research Center</pub><pmid>32798231</pmid><doi>10.22037/uj.v16i7.5985</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1735-1308
ispartof Urology journal, 2021-07, Vol.18 (4), p.395-399
issn 1735-1308
1735-546X
language eng
recordid cdi_proquest_miscellaneous_2434479358
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Aged
Aged, 80 and over
Biopsy
Biopsy, Needle
Cancer surgery
Cross-Sectional Studies
Humans
Iran
Male
Middle Aged
Neoplasm Grading
Prostate
Prostate cancer
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms - surgery
Retrospective Studies
Seminal Vesicles
Urological surgery
title The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A05%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Discrepancy%20between%20Needle%20Biopsy%20and%20Radical%20Prostatectomy%20Gleason%20Score%20in%20Patients%20with%20Prostate%20Cancer&rft.jtitle=Urology%20journal&rft.au=Abedi,%20Amir%20Reza&rft.date=2021-07-01&rft.volume=18&rft.issue=4&rft.spage=395&rft.epage=399&rft.pages=395-399&rft.issn=1735-1308&rft.eissn=1735-546X&rft_id=info:doi/10.22037/uj.v16i7.5985&rft_dat=%3Cproquest_pubme%3E2819508523%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2819508523&rft_id=info:pmid/32798231&rfr_iscdi=true